SCHEMBL10247697

SCHEMBL10247697

CN(Cc1ccccc1)C(=O)CCCSc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.66
RAB9A P51151 3/20 0.66
KMT2A Q03164 1/20 0.60
ALDH1A1 P00352 2/20 0.57
BCHE P06276 2/20 0.49
ACHE P22303 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
CA12 O43570 1/20 0.49
CA9 Q16790 1/20 0.49
POLB P06746 1/20 0.47
HPGD P15428 1/20 0.47
RIPK1 Q13546 1/20 0.47
ACKR3 P25106 1/20 0.46
CDK4 P11802 1/20 0.46
AOC3 Q16853 1/20 0.46
TSPO P30536 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL418467 0.92 NPC1 (0.59) NPC1RAB9AKMT2AALDH1A1BCHE
SCHEMBL416207 0.88 MAPK1 (0.60) NPC1RAB9AKMT2AALDH1A1BCHE
SCHEMBL418540 0.88 NPC1 (0.55) NPC1RAB9AKMT2AALDH1A1BCHE
SCHEMBL4072151 0.84 NPC1 (0.85) NPC1RAB9AKMT2AALDH1A1BCHE
SCHEMBL571146 0.83 ALDH1A1 (0.66) NPC1RAB9AKMT2AALDH1A1SMN1; SMN2
SCHEMBL411317 0.80 NPC1 (0.45) NPC1RAB9AKMT2AALDH1A1BCHE
SCHEMBL2485825 0.80 LMNA (0.47) NPC1RAB9AKMT2ASMN1; SMN2RIPK1
SCHEMBL417283 0.80 NPC1 (0.43) NPC1RAB9AKMT2AALDH1A1POLB
SCHEMBL16831598 0.80 NPC1 (0.77) NPC1RAB9AKMT2AALDH1A1BCHE
SCHEMBL4074355 0.80 NPC1 (0.77) NPC1RAB9AKMT2AALDH1A1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS HAVCR2, MAVS, EIF2AK2 NPC1 76/4885RAB9A 646/4885KMT2A 2843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.